EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Hypoxia shapes both therapeutic response and resistance in metastatic clear cell renal cell carcinoma

Lynda Vuong, Andrew E Cornish, Jennifer Pfeil, Yash Khandwala, Hui Jiang, Doris X T Zheng, Eduardo A Mascareno, Nicole Rittenhouse, Phillip M Rappold, Josef Leibold, Erich A Sabio, Kate Weiss und 28 weitere

Cancer Cell · 2026

DOI: 10.1016/j.ccell.2026.05.007 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Cell, 2026. Verfasst von Lynda Vuong und 39 weiteren Autor:innen. Beteiligte Einrichtung: Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Human Oncology and Pathogenesis Program, Memorial …. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Kidney Neoplasms, Drug Resistance, Neoplasm. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 119 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, National Institutes of Health, Marie-Josée and Henry R. Kravis Center for Molecular Oncology.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Vascular endothelial growth factor receptor-targeting tyrosine kinase inhibitors (VEGFR-TKIs) and anti-PD-1 (aPD-1) combinations are effective in multiple solid tumors, particularly in clear cell renal cell carcinoma (ccRCC), due to its characteristic pseudohypoxic, hyper-angiogenic state driven by biallelic VHL loss. However, long-term durability is inferior to dual aPD-1/anti-CTLA-4 regimens, yet the underlying mechanisms remain unclear. We investigated tumor microenvironment evolution following VEGFR-TKI, aPD-1, and combined VEGFR-TKI/aPD-1 treatment in a transgenic ccRCC mouse model. We identify hypoxia-responsive SPP1+ tumor-associated macrophages (TAMs) that infrequently infiltrate baseline pseudohypoxic tumors. This proxy of true hypoxia tracks with successful response to VEGFR-TKI/aPD-1 in mouse and human on-treatment single-cell RNA sequencing and imaging mass cytometry cohorts, reflecting treatment-induced hypoxic necrosis. Paradoxically, pretreatment hypoxia predicted worse outcomes across VEGFR-TKI/aPD-1 trials and real-world cohorts while extended exposure to hypoxia-inducing VEGFR-TKIs exacerbated metastasis in mice, highlighting the dual implications of hypoxia in ccRCC disease trajectory.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Renal CellKidney NeoplasmsDrug Resistance, NeoplasmAnimalsHumansMiceTumor MicroenvironmentProtein Kinase InhibitorsTumor-Associated MacrophagesMice, TransgenicImmune Checkpoint InhibitorsTumor Hypoxia

Stichwörter der Autor:innen

GPNMBSPP1angiogenesis inhibitorsclear cell renal cell carcinomahypoxiaimmune checkpoint blockadepseudohypoxiatumor microenvironmenttumor-associated macrophagesvascular normalization

Substanzen

Protein Kinase InhibitorsImmune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA. Electronic address:…
  • Immunology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Department of Medicine, Genitourinary Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Lunenfeld Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, ON, Canada; Department of Molecular Genetics, University of Toronto, Toronto, ON, Canada.
  • Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Cancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Department of Medical Oncology and Pneumology (Internal Medicine VIII), University Hospital Tuebingen, Tuebingen, Germany;…

Förderung

  • NCI NIH HHS
  • National Institutes of Health
  • Marie-Josée and Henry R. Kravis Center for Molecular Oncology
  • Cycle for Survival
  • US Department of Defense

Zitieren

APA

Vuong, L., Cornish, A. E., Pfeil, J., Khandwala, Y., Jiang, H., Zheng, D. X. T., Mascareno, E. A., Rittenhouse, N., Rappold, P. M., Leibold, J., Sabio, E. A., Weiss, K., Gonzalez, C., Ji, L., Zhang, J., Adlesic, M., Akin, O., Flynn, J., Krishna, C., …, & Hakimi, A. A. (2026). Hypoxia shapes both therapeutic response and resistance in metastatic clear cell renal cell carcinoma. Cancer Cell. https://doi.org/10.1016/j.ccell.2026.05.007

Vancouver

Vuong L, Cornish AE, Pfeil J, Khandwala Y, Jiang H, Zheng DXT, et al. Hypoxia shapes both therapeutic response and resistance in metastatic clear cell renal cell carcinoma. Cancer Cell. 2026. doi:10.1016/j.ccell.2026.05.007

BibTeX
@article{Vuong2026,
  author = {Vuong, Lynda and Cornish, Andrew E and Pfeil, Jennifer and Khandwala, Yash and Jiang, Hui and Zheng, Doris X T and Mascareno, Eduardo A and Rittenhouse, Nicole and Rappold, Phillip M and Leibold, Josef and Sabio, Erich A and Weiss, Kate and Gonzalez, Carlene and Ji, Liangliang and Zhang, Jing and Adlesic, Mojca and Akin, Oguz and Flynn, Jessica and Krishna, Chirag and Lopez Sanmiguel, Andrea and Sager, Rebecca A and Tan, Tiak J and Sanchez, Alejandro and Di Natale, Renzo G and Blum, Kyle A and Russo, Paul and Coleman, Jonathan A and Frew, Ian J and Chowell, Diego and Chen, Ying-Bei and Solit, David B and Ostrovnaya, Irina and Motzer, Robert J and Voss, Martin H and Kotecha, Ritesh R and Chan, Timothy A and Jackson, Hartland W and Kuo, Fengshen and Li, Ming O and Hakimi, A Ari},
  title = {Hypoxia shapes both therapeutic response and resistance in metastatic clear cell renal cell carcinoma},
  journal = {Cancer Cell},
  year = {2026},
  doi = {10.1016/j.ccell.2026.05.007}
}
Kostenlos starten →